In an Italian compassionate use program of CPX-351 in older adults with newly diagnosed therapy-related AML or AML-MRC [39], MRD negativity was observed in 38% and 54% of patients assessed with MFC (n = 40) and WT1 qPCR (n = 38) methods, respectively. The gene discussed is WT1; the disease is acute myeloid leukemia.